Gedeon Richter PLC (RGEDF)
| Market Cap | 7.39B +41.4% |
| Revenue (ttm) | 2.84B +8.3% |
| Net Income | 710.14M -2.9% |
| EPS | 3.88 -2.8% |
| Shares Out | n/a |
| PE Ratio | 10.40 |
| Forward PE | 8.05 |
| Dividend | 1.44 (3.39%) |
| Ex-Dividend Date | Jun 3, 2025 |
| Volume | 251 |
| Average Volume | 50 |
| Open | 43.99 |
| Previous Close | 43.36 |
| Day's Range | 41.52 - 43.99 |
| 52-Week Range | 29.00 - 45.28 |
| Beta | 0.33 |
| RSI | 51.04 |
| Earnings Date | May 12, 2026 |
About Gedeon Richter
Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products. It offers women’s healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids; and Femtech, a digital therapeutic solution to enhance women’s lives. It also provides central nervous system products, such as products for the treatment of chronic cerebral circulatory disorders and neuropathic pain; and anaesthetics, anti-anxiety medications, sleeping pills, and anti-epileptic medicines, as we... [Read more]
Financial Performance
In 2025, Gedeon Richter's revenue was 928.96 billion, an increase of 8.33% compared to the previous year's 857.55 billion. Earnings were 232.34 billion, a decrease of -2.89%.
Financial numbers in HUF Financial StatementsNews
Gedeon Richter Plc.: Side-by-Side Conference Hosts Close to 800 Participants in Malta to Advance Women's Health Care
Gedeon Richter's Side-by-Side Conference on Advancing Women's Health brought together Healthcare practitioners from 40 countries for a dynamic two-day exchange on March 26-27, making it the largest...
Gedeon Richter Earnings Call Transcript: Q4 2025
2025 ended with strong revenue and profit growth, led by Women's Health and innovative products, despite FX losses and a challenging macro environment. Outlook for 2026 is high single-digit growth, with continued investment in R&D and new product launches.
Gedeon Richter Plc.: Richter Extends Its Support to Africa - The First Year of the House of Hope in Bamako in Numbers
The First Year of the House of Hope in Bamako in Numbers BUDAPEST, HU / ACCESS Newswire / January 26, 2026 / Nearly one year has passed since the House of Hope centre, established by Richter Gedeon...
Gedeon Richter Earnings Call Transcript: Q3 2025
Q3 2025 saw strong growth in innovative segments but was offset by headwinds in GenMed and CDMO, leading to a temporary revenue slowdown. Free cash flow hit a record high, and full-year Clean EBIT is projected to grow 8%-10%. Gross margin is expected to improve in Q4.
Gedeon Richter Earnings Call Transcript: Q2 2025
First half results show strong revenue and clean EBIT growth, led by women's health and neuropsychiatry, with robust pipeline progress and ESG achievements. Inventory write-offs and FX volatility impacted margins, but full-year guidance remains on track.
Gedeon Richter Earnings Call Transcript: Q1 2025
Q1 2025 saw strong revenue and EBIT growth, driven by pharma sales and FX gains, with robust free cash flow and a solid cash position. Four biosimilar launches are planned within 12 months, and the outlook for general medicines and women's health remains positive.
Gedeon Richter Earnings Call Transcript: Q4 2024
Revenue and profit grew strongly in 2024, with all business units contributing and free cash flow nearly tripling. 2025 guidance targets 10% growth amid lower milestone income and cost control initiatives.
Gedeon Richter Earnings Call Transcript: Q3 2024
Revenue and net profit grew strongly year-over-year, driven by broad-based segment growth and successful M&A. Free cash flow and EBIT improved, with new product launches and biosimilar filings supporting future outlook. FX volatility and regulatory uncertainties remain key risks.
Gedeon Richter Transcript: Investor Update
Recent acquisitions have vertically integrated the business, expanded R&D, and secured control over key assets like E4, positioning the company as a leader in women's health innovation. Ambitions include surpassing €1 billion in sales and achieving over 20% EBIT margin, with new product launches and market expansion driving growth.